# AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure

> **NCT03360448** · PHASE3 · WITHDRAWN · sponsor: **Renova Therapeutics**

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Ad5.hAC6
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03360448
- **Lead sponsor:** Renova Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06
- **Primary completion:** 2020-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Clinical development plans and strategy for RT-100 being re-evaluated
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360448, "AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03360448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*